Post-earnings recap
Reported
Wed, Feb 12, 2025
EPS actual
$-0.40
EPS est.
$-0.32
EPS surprise
-24.22%
1-day move
+1.52%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is facing challenges, particularly reflected in its EPS miss. However, the stock rose by 1.52%, suggesting that investors may be optimistic about the company's long-term potential and management's focus on innovation despite current difficulties.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | -24.22% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions but remained focused on future opportunities. They reiterated their commitment to innovation.
Management acknowledged challenges but emphasized ongoing innovation efforts.
They highlighted a commitment to long-term growth despite short-term setbacks.